12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Votubia everolimus regulatory update

The European Commission approved Votubia everolimus to treat renal angiomyolipoma associated with tuberous sclerosis complex (TSC) in adults who are at risk of complications but who do not require immediate surgery. Novartis markets everolimus as Afinitor in the U.S. and EU to treat advanced renal cell carcinoma, neuroendocrine tumors of pancreatic...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >